347 related articles for article (PubMed ID: 25516844)
1. Trypanosomatids topoisomerase re-visited. New structural findings and role in drug discovery.
Balaña-Fouce R; Alvarez-Velilla R; Fernández-Prada C; García-Estrada C; Reguera RM
Int J Parasitol Drugs Drug Resist; 2014 Dec; 4(3):326-37. PubMed ID: 25516844
[TBL] [Abstract][Full Text] [Related]
2. Novel findings on trypanosomatid chemotherapy using DNA topoisomerase inhibitors.
Díaz-González R; Pérez-Pertejo Y; Prada CF; Fernández-Rubio C; Balaña-Fouce R; Reguera RM
Mini Rev Med Chem; 2009 Jun; 9(6):674-86. PubMed ID: 19519493
[TBL] [Abstract][Full Text] [Related]
3. Biology of human pathogenic trypanosomatids: epidemiology, lifecycle and ultrastructure.
Rodrigues JC; Godinho JL; de Souza W
Subcell Biochem; 2014; 74():1-42. PubMed ID: 24264239
[TBL] [Abstract][Full Text] [Related]
4. DNA Topoisomerases of Leishmania Parasites; Druggable Targets for Drug Discovery.
Reguera RM; Elmahallawy EK; García-Estrada C; Carbajo-Andrés R; Balaña-Fouce R
Curr Med Chem; 2019; 26(32):5900-5923. PubMed ID: 29773051
[TBL] [Abstract][Full Text] [Related]
5. [Type I DNA topoisomerase from protozoan pathogens as a potential target for anti-tumoral drugs].
Reguera RM; Pérez-Pertejo Y; Redondo CM; Díaz-González R; Balaña-Fouce R
Medicina (B Aires); 2007; 67(6 Pt 2):747-57. PubMed ID: 18422072
[TBL] [Abstract][Full Text] [Related]
6. Nuclear DNA replication and repair in parasites of the genus Leishmania: Exploiting differences to develop innovative therapeutic approaches.
Uzcanga G; Lara E; Gutiérrez F; Beaty D; Beske T; Teran R; Navarro JC; Pasero P; Benítez W; Poveda A
Crit Rev Microbiol; 2017 Mar; 43(2):156-177. PubMed ID: 27960617
[TBL] [Abstract][Full Text] [Related]
7. Targeting calcium homeostasis as the therapy of Chagas' disease and leishmaniasis - a review.
Benaim B; Garcia CR
Trop Biomed; 2011 Dec; 28(3):471-81. PubMed ID: 22433874
[TBL] [Abstract][Full Text] [Related]
8. Antiparasitic chemotherapy: tinkering with the purine salvage pathway.
Datta AK; Datta R; Sen B
Adv Exp Med Biol; 2008; 625():116-32. PubMed ID: 18365663
[TBL] [Abstract][Full Text] [Related]
9. Effect of topoisomerase inhibitors and DNA-binding drugs on the cell proliferation and ultrastructure of Trypanosoma cruzi.
Zuma AA; Cavalcanti DP; Maia MC; de Souza W; Motta MC
Int J Antimicrob Agents; 2011 May; 37(5):449-56. PubMed ID: 21292448
[TBL] [Abstract][Full Text] [Related]
10. Cell death pathways in pathogenic trypanosomatids: lessons of (over)kill.
Menna-Barreto RFS
Cell Death Dis; 2019 Jan; 10(2):93. PubMed ID: 30700697
[TBL] [Abstract][Full Text] [Related]
11. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
12. Characterizing the bi-subunit type IB DNA topoisomerase of Leishmania parasites; a novel scenario for drug intervention in trypanosomatids.
Reguera RM; Díaz-González R; Pérez-Pertejo Y; Balaña-Fouce R
Curr Drug Targets; 2008 Nov; 9(11):966-78. PubMed ID: 18991609
[TBL] [Abstract][Full Text] [Related]
13. Ornithine decarboxylase and S-adenosylmethionine decarboxylase in trypanosomatids.
Persson L
Biochem Soc Trans; 2007 Apr; 35(Pt 2):314-7. PubMed ID: 17371268
[TBL] [Abstract][Full Text] [Related]
14. DNA topoisomerases in apicomplexan parasites: promising targets for drug discovery.
García-Estrada C; Prada CF; Fernández-Rubio C; Rojo-Vázquez F; Balaña-Fouce R
Proc Biol Sci; 2010 Jun; 277(1689):1777-87. PubMed ID: 20200034
[TBL] [Abstract][Full Text] [Related]
15. Topoisomerase research of kinetoplastid parasite Leishmania, with special reference to development of therapeutics.
Das BB; Sen N; Dasgupta SB; Ganguly A; Das R; Majumder HK
Indian J Med Res; 2006 Mar; 123(3):221-32. PubMed ID: 16778306
[TBL] [Abstract][Full Text] [Related]
16. [Poisons of DNA topoisomerases I and II].
Charcosset JY; Soues S; Laval F
Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
[TBL] [Abstract][Full Text] [Related]
17. Conventional therapy and promising plant-derived compounds against trypanosomatid parasites.
Alviano DS; Barreto AL; Dias Fde A; Rodrigues Ide A; Rosa Mdo S; Alviano CS; Soares RM
Front Microbiol; 2012; 3():283. PubMed ID: 22888328
[TBL] [Abstract][Full Text] [Related]
18. The ever unfolding story of cAMP signaling in trypanosomatids: vive la difference!
Tagoe DN; Kalejaiye TD; de Koning HP
Front Pharmacol; 2015; 6():185. PubMed ID: 26441645
[TBL] [Abstract][Full Text] [Related]
19. DNA topoisomerase I from parasitic protozoa: a potential target for chemotherapy.
Reguera RM; Redondo CM; Gutierrez de Prado R; Pérez-Pertejo Y; Balaña-Fouce R
Biochim Biophys Acta; 2006; 1759(3-4):117-31. PubMed ID: 16757380
[TBL] [Abstract][Full Text] [Related]
20. Comparative analysis of the kinomes of three pathogenic trypanosomatids: Leishmania major, Trypanosoma brucei and Trypanosoma cruzi.
Parsons M; Worthey EA; Ward PN; Mottram JC
BMC Genomics; 2005 Sep; 6():127. PubMed ID: 16164760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
